Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 8/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12097011 | 0.93 | CYP3A4 (0.39) | CYP3A4CYP2C19CYP2D6CYP2C9HTR6 | |
| SCHEMBL28947517 | 0.85 | HTT (0.33) | CYP3A4CYP2C19CYP2D6CYP2C9HIF1A | |
| SCHEMBL12096669 | 0.82 | CYP3A4 (0.38) | CYP3A4CYP2C19CYP2D6CYP2C9HTR6 | |
| SCHEMBL12096810 | 0.78 | POLB (0.41) | CYP3A4CYP2C19CYP2D6CYP2C9HTR6 | |
| SCHEMBL12096717 | 0.78 | MRGPRX4 (0.43) | CYP3A4CYP2C19CYP2D6CYP2C9PPARG | |
| SCHEMBL27936040 | 0.78 | ITK (0.33) | CYP3A4CYP2C19CYP2D6CYP2C9PPARG | |
| SCHEMBL12096843 | 0.78 | HIF1A (0.41) | CYP3A4CYP2C19CYP2D6CYP2C9HIF1A | |
| SCHEMBL12096702 | 0.77 | PTGER1 (0.43) | CYP3A4CYP2C19CYP2D6CYP2C9HTR6 | |
| SCHEMBL12096824 | 0.77 | PPARG (0.46) | CYP3A4CYP2C19CYP2D6CYP2C9HTR6 | |
| SCHEMBL12096609 | 0.76 | PPARG (0.51) | CYP3A4CYP2C19CYP2D6CYP2C9PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | CYP3A4 2941/4885CYP2C19 2424/4885CYP2D6 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.